Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-718-4 | CAS number: 109-92-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Health surveillance data
Administrative data
- Endpoint:
- health surveillance data
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific standards, well documented and acceptable for assessment
Data source
Reference
- Title:
- No information
- Author:
- Sadove MS, Wyant GM, and Cletcher JO (1955). Ethyl vinyl|ether: Pharmacological and clinical evaluation. Curr. Res.|Anaesth. Analg. 34 (4), 235-240.
Materials and methods
- Study type:
- human medical data
Test material
- Reference substance name:
- Ethyl vinyl ether
- EC Number:
- 203-718-4
- EC Name:
- Ethyl vinyl ether
- Cas Number:
- 109-92-2
- Molecular formula:
- C4H8O
- IUPAC Name:
- ethoxyethene
Constituent 1
Results and discussion
Any other information on results incl. tables
RS-Freetext:
Following pharmacological animal studies in the end 1940s
EVE was first administered to a human being in 1947.
Thereafter it was used in large series for the induction of
anesthesia in children.
In the animal studies, EVE did not significantly change
blood pressure, Electrocardiogram (ECG),
Electroencephalogram (EEG), blood urea, carbon dioxide
combining power. There was no hemolysis. Clotting time was
increased by 10-15%. Liver function was normal, and there
were no pathological changes noted in liver and kidney.
Clinical properties of EVE as an anesthetic in humans:
Induction: rapid
Maintenance: easy
Irritation: slight
Salivary excretion: marked
Relaxation: fair
Running movements: occur
Emergence Not likely
Nausea and vomiting: fairly common
The pharmacological effects were studied in 29 patients,
aged 14 to 58 years (7 males, 22 females). Gynecological and
orthopedic cases prevailed. EVE was used in combination with
other common anesthetics. In brief, findings were as
follows:
Liver function was unchanged in 58% of the patients.
Bromsulphthalein excretion was observed in some cases. In
two of these, large doses up to 110 ml EVE had been used.
Urinalysis: no changes were noted in 68% of the patients.
Six patients (20%) showed findings (traces of acetone (n=6),
increased sugar (n=2), traces of albumin (n=3) which had
returned to normal on day 5 post treatment.
Blood: no changes in 82% of the patients; the remainder
showed slight leucocytosis.
ECG: no change in 48% of the patients. Tachycardia,
auricular and ventricular premature contractions were all
seen. Mild myocardial depression was noted in 5 cases (17%).
Nausea, vomiting: was seen in 10 out of 29 patients.
Salivation: was quite severe at times; was treatable with
atropine.
Applicant's summary and conclusion
- Conclusions:
- CL-Freetext:
The authors concluded that EVE was a useful and in many
respect a safer anesthetic in children than divinylether.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
